Zobrazeno 1 - 10 of 14 pro vyhledávání: '"H. B. Breitz"'
1
Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
Autor: John R. Eckardt, H. B. Breitz, Dimitri L. Bentsion, G. S. Baker, Igor S. Polyakov, David A. Karlin, Frederick R. MacKintosh, Oleg Lipatov
Publikováno v: Journal of Clinical Oncology. 27:2046-2051
Purpose This study was designed to confirm the efficacy and safety of picoplatin, a cisplatin analog designed to overcome platinum resistance, in patients with small-cell lung cancer (SCLC) with platinum-refractory/-resistant disease. Patients and Me
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882949b10b45a491dd770335fdcb9b37
https://doi.org/10.1200/jco.2008.19.3235
Zobrazit plný text záznamu
2
Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method
Autor: M G, Stabin, J A, Siegel, R B, Sparks, K F, Eckerman, H B, Breitz
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 42(3)
The contribution to red marrow absorbed dose from beta-emitting radionuclides distributed uniformly in the total body can be overestimated using either MIRD 11 or MIRDOSE3. The S value assigned to the red marrow target region from activity distribute
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cbb66fe13f9d79ab10714830d81e68c6
https://pubmed.ncbi.nlm.nih.gov/11337528
Zobrazit plný text záznamu
4
Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry
Autor: M G, Stabin, H B, Breitz
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(5)
The excretion of radiopharmaceuticals in breast milk is studied to understand excretion mechanisms and to determine recommended breast feeding interruption times for many compounds based on the radiation absorbed dose estimated. A literature review i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bdd1a1f6358a863698dfd347bbc68652
https://pubmed.ncbi.nlm.nih.gov/10809203
Zobrazit plný text záznamu
5
Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin
Autor: H B, Breitz, P L, Weiden, P L, Beaumier, D B, Axworthy, C, Seiler, F M, Su, S, Graves, K, Bryan, J M, Reno
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(1)
Pretargeted radioimmunotherapy (PRIT) was evaluated using an antibody-streptavidin conjugate, followed by a biotin-galactose-human serum albumin clearing agent and 90Y-dodecane tetraacetic acid (DOTA)-biotin as the final step for therapy. The objecti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5e8eb8568116373aad686afd8928c69a
https://pubmed.ncbi.nlm.nih.gov/10647616
Zobrazit plný text záznamu
6
Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results
Autor: H B, Breitz, J S, Durham, D R, Fisher, P L, Weiden
Publikováno v: Cancer research. 55
The radiation-absorbed dose was estimated following i.p. administration of a 186Re-labeled murine antibody, NR-LU-10, in 27 patients with advanced ovarian cancer. Data for the dosimetry estimation were obtained from quantitative gamma camera imaging
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2c26b8f3cfb0bf241c8680dcde5f3f6e
https://pubmed.ncbi.nlm.nih.gov/7493352
Zobrazit plný text záznamu
7
Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody
Autor: H B, Breitz, J S, Durham, D R, Fisher, P L, Weiden, G L, DeNardo, H M, Goodgold, W B, Nelp
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 36(5)
Pharmacokinetics, biodistribution and radiation dose estimates following intraperitoneal administration of a 186Re-labeled murine antibody, NR-LU-10, were assessed in 27 patients with advanced ovarian cancer.Quantitative gamma camera imaging and gamm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::40404e0ba90aa4dcc998bb952687c387
https://pubmed.ncbi.nlm.nih.gov/7738644
Zobrazit plný text záznamu
8
Human anti-mouse antibody suppression with cyclosporin A
Autor: P L, Weiden, S B, Wolf, H B, Breitz, J W, Appelbaum, C A, Seiler, R, Mallett, M J, Bjorn, F M, Su, M F, Fer, D, Salk
Publikováno v: Cancer. 73
Cyclosporin was used in an attempt to suppress the formation of human antimouse antibody (HAMA) after administration of murine monoclonal antibodies.Thirteen patients were given oral cyclosporin (8.6-15 mg/kg/day) starting 2 days before administratio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::163546114c72d8330521ab1384eb51dc
https://pubmed.ncbi.nlm.nih.gov/8306252
Zobrazit plný text záznamu
9
Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10
Autor: P L, Weiden, H B, Breitz, C A, Seiler, M J, Bjorn, B A, Ratliff, R, Mallett, P L, Beaumier, J W, Appelbaum, A R, Fritzberg, D, Salk
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 34(12)
A mouse-human chimeric monoclonal antibody (NR-LU-13), with the same pancarcinoma antigen recognition site as a previously studied murine monoclonal antibody (NR-LU-10), was radiolabeled with 186Re using a bifunctional chelate. Nine patients (ages 31
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e2fbc16e9d36595629830aa39c67733a
https://pubmed.ncbi.nlm.nih.gov/8254397
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje